Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Alpha Methyl Tetradecylthioacetic Acid (also known as Tetradecylthioacetic Acid, or TTA) is a synthetic fatty acid analog that has been investigated primarily in Scandinavia for its effects on lipid metabolism. Preclinical studies, particularly in rodents, have shown that TTA can modulate lipid metabolism by acting as a peroxisome proliferator-activated receptor (PPAR) agonist, especially PPAR-alpha. Activation of PPAR-alpha is associated with increased fatty acid oxidation, reduced triglyceride synthesis, and improved lipid profiles. In animal studies, TTA supplementation led to decreased plasma triglycerides and cholesterol, as well as beneficial effects on fatty liver and obesity markers. Human evidence is more limited. A handful of small clinical trials suggest that TTA may reduce plasma triglyceride levels and influence certain metabolic parameters in overweight subjects and patients with combined hyperlipidemia. For example, a randomized, placebo-controlled trial (Nenseter et al., 1999) demonstrated modest triglyceride-lowering effects in humans. However, the overall number of studies is small, sample sizes are limited, and long-term safety and efficacy data are lacking. There is insufficient evidence to support its widespread therapeutic use for poor fat metabolism, and regulatory approval for metabolic disorders is not established. Thus, while the mechanistic rationale is supported by preclinical data, the clinical validation remains preliminary.

More about alpha Methyl Tetradecylthioacetic Acid
More about Fat Metabolism (poor)

Other ingredients used for Fat Metabolism (poor)

Other health conditions supported by alpha Methyl Tetradecylthioacetic Acid

Products containing alpha Methyl Tetradecylthioacetic Acid